CSL Biotherapies Company Profile

20:55 EDT 26th March 2019 | BioPortfolio

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling and packaging services out of CSL’s Kankakee, Illinois and Marburg, Germany facilities. These facilities have the capability to produce seasonal and pandemic influenza vaccines in thimerosal-free, pre-filled, single-use syringes and in multi-dose vials containing preservative.


P.O. Box 604461020 First Avenue
King of Prussia
United States of America



News Articles [11 Associated News Articles listed on BioPortfolio]

Gamida Cell and Be The Match BioTherapies Announce Strategic Collaboration

Gamida Cell (Nasdaq:GMDA), a leading cellular and immune therapeutics company, and Be The Match BioTherapies, a subsidiary of the National Marrow Donor Program®/Be The Match® offering integrated ...

Be The Match BioTherapies, Cryoport Enter Agreement

To deliver end-to-end supply chain services to the cell and gene therapy industry

Be The Match BioTherapies® Announces Collaboration with National Health Service Blood and ...

Collaboration aims to streamline access to authorized collection and processing centers Read more...

Be The Match BioTherapies® Strengthens International Network to Provide Global Support for Cell and Gene Therapy Companies

Collaboration with Cellex Cell Professionals to Support International Standardization of the Cell Therapy Industry Experienced Apheresis Network Manager Petr Machalik App...

Be The Match BioTherapies® Announces Launch of Quality System Audit Program (QSAP) to Enable Faster Onboarding of Cell Collection Facilities

New program to provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks while minimizing quality system audit bu...

Be The Match BioTherapies® Announces Collaboration with National Health Service Blood and Transplant of the United Kingdom

Collaboration aims to streamline access to authorized collection and processing centers Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing ...

Trend Chart on Innovative Biotherapies – February 11th, 2019

 FEATURE STORY ● Luxturna®: FDA documents reveal the value of a costly gene therapy GENE THERAPY ● The application of Adeno-Associated Viral vector gene therapy to the treatment of Fragile X Sy...

[Comment] Ustekinumab: a promising new drug for SLE?

In The Lancet, Ronald van Vollenhoven and colleagues1 report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) mon...

Drugs and Medications [0 Results]


PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Changes in persistent asthma care and outcomes from 2006 to 2016 in France.

Changes in asthma care need to be documented at arrival of biotherapies.

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis.

Three biotherapies - etanercept, adalimumab, and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. Howe...

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.

Unexpected high disease activity (UHDA) after Fingolimod withdrawal has recently become a controversial concern for physicians. Here, we report the case of a patient with severe exacerbation of MS aft...

New treatments in respiratory medicine in 2018 : asthma, cystic fibrosis and nocturnal positive pressure (CPAP or NIV).

In this review of novel therapies in pulmonary disorders in 2018, we cover 3 different entities. In GINA stage 1 and 2 asthma, new strategies allow a more individualized treatment. In more severe asth...

Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a systemic necrotizing vasculitis of small- and medium-size vessels, characterized by asthma and blood ...

Clinical Trials [13 Associated Clinical Trials listed on BioPortfolio]

Biotherapies and Therapeutic Education in Chronic Inflammatory Rheumatism

The hypothesis is that group interaction associated with individual interviews intensify the acquisition of safety skills compared to individual interviews alone in patients with CIR treat...

COLISURG Prospective, Multicentric Cohort

The surgical treatment of the ulcerative colitis (UC) remains associate to a significant morbidity (up to 60%). Anastomotic fistula and pelvic sepsis are the most severe complications whic...

Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis

PSOBIOTEQ is a national multicentric prospective cohort of cutaneous psoriasis patients receiving systemic treatment (biotherapy or DMARDs) for moderate to severe cutaneous psoriasis. It i...

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease. This algorithm will h...

Impact of Behavioral Factors on Treatment Adherence in a Sample of Rheumatoid Arthritis Patients

Rheumatoid arthritis (RA) care has been revolutionized in the last decade with the advent of biotherapies. Only 66% of treated patients are compliant. Nevertheless, studies analyzing the m...

Companies [4 Associated Companies listed on BioPortfolio]

Biotherapies Incorporated

Biotherapies, Inc developing a new therapy and diagnostics for breast cancer. Access to company information, technology and research updates provided.

Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development—from discovery through commercialization. Built...

CSL Biotherapies

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling...

Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, Cal...

More Information about "CSL Biotherapies" on BioPortfolio

We have published hundreds of CSL Biotherapies news stories on BioPortfolio along with dozens of CSL Biotherapies Clinical Trials and PubMed Articles about CSL Biotherapies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CSL Biotherapies Companies in our database. You can also find out about relevant CSL Biotherapies Drugs and Medications on this site too.

Quick Search


Relevant Topics

Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Corporate Database Quicklinks

Searches Linking to this Company Record